

A COMPREHENSIVE REVIEW ON ADVANCEMENTS IN TADALAFIL FORMULATION AND TRANSDERMAL DELIVERY

¹Harshal Bhagwan Patil, ²Mohammed Awais, ³Shaikh Habiburrahman, ⁴Momin Sanaurrehman,
⁵Mrunal K Shirsat

¹Student, ²Professor, ³Professor, ⁴Professor, ⁵Principal

¹Dr. Uttamrao Mahajan college of b pharmacy, Chalisgaon, India

ABSTRACT:

Consequently, the developments in transdermal delivery systems for Tadalafil are a shift in the management of erectile dysfunction and benign prostatic hyperplasia. The main disadvantages of conventional oral formulations are poor absorption, first-pass metabolism, and a number of side effects that may compromise patient compliance. Nonetheless, there are drawbacks associated with these formulation types, which have been overcome to a large extent by transdermal formulations such as patches and formulations at the nano scale. Further, the slow and sustained release typical of transdermal delivery has been linked to lessened system toxicities, thus improving patient compliance. It has also reduced the bioavailability and steady state drug concentrations than that of transdermal Tadalafil, which increases the therapeutic efficacy. Research work has also started to support these innovations and the potential of the transdermal Tadalafil in offering better results than the oral Tadalafil has been proved. Further studies are being conducted on the ways to improve the efficiency of Tadalafil administration, and all of them show a positive trend in this regard. Subsequent studies will also be required to determine uniform transdermal formulations and elaborate on therapeutic possibilities in uncommon patient groups. As the methods of transdermal drug delivery develop all over the world, the possibility to enhance the usage of Tadalafil for patients can be seen. This shift is not only expected to increase the effectiveness of therapy but also to increase the general quality of life of patients. Transdermal Tadalafil can be considered a new moving step in the search for which the most adequate therapeutic solution for erectile dysfunction may exist.

Keywords: Tadalafil, Delivery system, Oral Bioavailability, Nano-formulations.

I. INTRODUCTION

Some physicians prescribe tadalafil for men who have ED or BPH because this agent belongs to the group of (PDE5) inhibitors [1]. How it does this is by reducing the tones of the smoother muscles within the penis thus promoting erection function besides enhancing the blood supply to this organ. Generic oral agents for Tadalafil have several drawbacks, whereas controlled drug has been verified to have an impact on erectile dysfunction and urinary signs. Essential issues include poor solubility, extensive pre-systemic elimination, and interday variability in drug intake. Some of the outcomes of these problems include; fluctuating therapy effectiveness and low therapy compliance [2]. However extemporaneous formulations and patches present new vistas for the management of these problems and the transdermal drug delivery systems (TDDS) are being developed as a new outlet in this field. Transdermal drug delivery systems are especially helpful in that a medicine can be administered through the skin, bypassing the gastrointestinal tract and first-pass effect

[3]. This method increases the bioavailability of Tadalafil, and besides, allows to achieve gradual and sustained release of the medicine that helps to avoid plasma concentration peaks and troughs. A further advantage of the transdermal approaches is that they provide better patient compliance than oral administration because of reduction of the systemic side effects [4]. New advanced technologies under TDDS for Tadalafil include, Transdermal patches, Nano formulations and permeation enhancer [5]. This review will explore these advances in the context of Tadalafil therapy through the enhancement of transdermal administration into further details indicating its possibilities, clinical impacts and perspectives [6].

2. Challenges of Oral Tadalafil Problems arising from oral formulation of Tadalafil are several and plays significant role in determining the therapeutic outcomes as well as patients' compliance even though the medicine has been confirmed to effectively manage erectile dysfunction and benign prostatic hyperplasia [7]. Oral Bioavailability and First-Pass Metabolism Among them, the oral bioavailability which ranges from 1436% for Tadalafil. Most of the medicine is metabolized within the liver before it gets into the blood stream, and this is why its bioavailability is very low [8]. This metabolic process makes the plasma concentrations vary, which leads to its therapeutic consequences to be inconsequential at the most. There are numerous factors that can affect absorption with food consumption being one of them; for instance, patients searching for that breakthrough moment to have the drug work may again be in for a surprise to discover that eating a high fat meal will slow the onset of such an effect [9].

Adverse Effects Related to Oral Administration

Possible side effects of tadalafil are back pains, nasal congestion, redness of the skin, heartburn, and headaches. Unfortunately, patients receive poor therapeutic experiences since these side effects are discouraging to continue with therapy and can significantly alter their quality of life. Patients and the physicians who prescribe them this drug should weigh the risk/benefit ratio because of the risk of interactions with nitrates [10].

Patient Compliance and Associated Issues

Any treatment that is prescribed really relies on the compliance of the person who has the illness. The drug substance is absorbed orally through the gastrointestinal tract but the use of oral Tadalafil may be erratic due to a variety of reasons such as gas formations, lower bioavailability and risk of side effects [11]. Due to the necessity of adjusting dosage to meal times or because of adverse effects that ensue patients may decide not to take the medicine or forget to take it all together. These problems with compliance therefore call for a new administration method of Tadalafil which are easier for the patient but have the same effective therapeutic index. Pharmacokinetics could be enhanced through TDDS in turn making the incidences of side effects decrease hence increasing patient compliance [12].

3. Formulation Approaches for Tadalafil Transdermal Delivery

Several formulation techniques of Transdermal Tadalafil delivery have been formulated due to the drawbacks that come along with oral delivery systems. Two of the most familiar techniques that attempt to enhance effectiveness are nanoencapsulation and transdermal systems [13].

3.1. Patches

The several approaches that are widely common and effective of delivering Tadalafil, and the patches cannot go unnoticed. These skin-adhering patches make the medicine slowly unravel in the patient's body for a long time [14]. Anticipated advantages of patch application are higher drug bioavailability, reduced first-pass effect and better patient compliance.

Tadalafil leave-donning patch formulation also works by using permeation enhancers to increase the likelihood that Tadalafil will pass through the skin's outer layer. These enhancers increase the size of the molecules of a drug to make them

penetrate the skin more easily by breaking the stratum corneum, the external layer of the skin for a while [15]. For the purpose of augmenting skin permeability without causative inflammation, the usage of chemicals known as permeation enhancers, such as ethanol, surfactants, and other fatty acids are incorporated. From the formulation and the use of suitable permeation enhancers, patches can discharge Tadalafil in a steady-state manner. This causes the plasma concentration to occur more prevalently and the therapeutic efficacy to be superior [16].

3.2. Nano-formulations

One new approach to enhance Tadalafil transdermal delivery system is with nano-formulations such as liposomal and nano-emulsified. The reconfinement of the medicine in liposome, a vesicular structure made up of phospholipid bilayer, provides it with better stability and certainly enhances its solubility in water [17]. Nano liposomes enhance penetration of substances in the dermal layers and can be made smaller to penetrate deeper into the skin. Nano emulsions on the other hand are small oil in water or water in oil emulsions of lipophilic drugs such as Tadalafil. Nano emulsions in general possess a greater surface area for absorption compared to macroemulsions and there is a better compatibility between the droplets and skin tissues. Other advantages of these formulations are that their skin permeability and drug absorption can be further improved if they are used in combination with permeation enhancers [18].

4. Pharmacokinetic Advantages of Transdermal Tadalafil

Pharmacokinetic properties of tadalafil transdermal administration systems have potential therapeutic advantages that can contribute to the enhanced therapeutic efficacy and satisfaction of patients [20].

Improved Bioavailability and Steady Drug Levels

Another advantage is a significantly higher Bioavailability of Transdermal Tadalafil in comparison with more traditional oral administration. Compared with oral administration, this delivery system raises the percent of the drug entering systemic circulation, since it does not have to pass through the GI tract and be subjected to first-pass metabolism [21]. Due to being metabolised in the liver, Tadalafil is only 15% absorbed through the oral route, which is very suitable for it. Tadalafil is better absorbed through transdermal patches or nanoformulations giving a higher concentration in plasma and more desirable therapeutic effects [22].

Also, Tadalafil can be delivered through skin in a preprogrammed and constant dose for an extended duration. This way of administering the drug controls the concentration of drug in the blood and not the up and down motion that is normally associated with this sort of delivery of drugs. It is therefore possible to have better counter variations compared to effects of intermittent oral administration so patients get better erectile performance or bladder symptoms [23].

Reduced Systemic Side Effects

Transdermal Tadalafil will therefore have less systemic adverse effects is another advantage that comes along with the delivery system [24]. Nausea, face flushes, and diarrhoea are some of the side effects associated with one that has used oral Tadalafil. From the past, this is because the drug achieves high plasma concentrations when taken orally. Nonetheless, the drug concentration is lower with transdermal route than with oral, because it takes time for the drug to be absorbed into the bloodstream. Steady-state

pharmacokinetics reduce the effects of side-effects of medication hence patients might be in a better position to adhere to well laid down prescription regimes [25]. Carrying out the administration of Transdermal Tadalafil, one can also reduce the potential interference and side effects posed by high plasma concentration; this will especially be so for clients who are on Multiple drugs [26]. Though different from other traditional oral drug delivery systems, transdermal systems for Tadalafil have their advantages in terms of pharmacokinetic characteristics, which enhance the therapeutic effect and reduce toxicity [27].

Oral Tablets	Tablets	Convenient and widely accepted	Low bioavailability, first-pass metabolism	Cialis
Transdermal Patches	Patches	Bypasses GI tract, steady release	Skin irritation, formulation stability	Tadalafil Transdermal Patch
Nanoemulsions	Liquid formulation	Enhanced skin permeation, improved solubility	Formulation complexity, stability issues	Tadalafil Nanoemulsion
Microneedle Patches	Solid patch	Painless delivery, rapid onset	Requires special equipment for application	Tadalafil Microneedles
Hydrogel Formulations	Gel	Moisturizing effect, controlled release	Limited skin penetration	Tadalafil Hydrogel
Liposomal Formulations	Liposomes	Targeted delivery, reduced side effects	Production cost, stability concerns	Tadalafil Liposomes
Emulsion-based Systems	Cream/Lotion	Enhanced absorption, patient-friendly	Formulation stability	Tadalafil Emulsion
Sustained-release Tablets	Tablets	Extended drug release, improved adherence	Potential for dose dumping	Extended-release Tadalafil
Ointments	Ointment	Localized effect, easy to apply	Messy application, potential for systemic absorption	Tadalafil Ointment
Film-forming Solutions	Film	Fast-drying, easy application	Requires careful handling	Tadalafil Film

5. Clinical Studies

Clinical studies looking at the safety and efficacy of Tadalafil delivered trans dermally based on patients' satisfaction have been carried out since switching from oral to transdermal delivery of this new modality

[29]. The increasing evidence on its effectiveness is shown in this section, including the major studies and current studies available yet.

Zhang et al. (2019) aimed at describing the pharmacokinetics, efficacy, and safety of Tadalafil transdermal patches in males with erectile dysfunction which is a frequent complaint [30]. The topical gel advanced erectile function scores in the trial significantly more than oral Tadalafil. Furthermore, the pharmacokinetics of the transdermal method was better with less side effects such as stable plasma levels and reduced peak concentration.

Continuing with the development of transdermal Tadalafil preparation, Kumar et al. and his team produced another important study in 2021 on preforming Tadalafil transdermal systems based on nanoemulsions [31]. They indicated the effects in animal model were better than those observed in animal model including increased skin penetration and improved therapeutic outcomes. According to the outcome, it is possible to assume that the nanoemulsion formulation may be as effective as oral Tadalafil while accompanied by much fewer side effects [32].

As of the current advancement in enhancing the delivery of Tadalafil through the skin further Researchers are now appreciating other methods of administration, including microneedle patches and liposomal formulations [33]. Ultimately, from what research data has been gathered early on, these relatively new technologies can enhance bioavailability and patient concordance even more.

From the research studies on Transdermal Tadalafil, there is likelihood of enhancing therapeutic outcomes and experiences in the patient [34]. Which makes it possible even in comparison with oral preparations of the medicine. There will still be further need for development of standardized method and formulations for more general use in clinical practice [35].

<i>Benefit</i>	<i>Description</i>	<i>Evidence Supporting-Benefit</i>	<i>Clinical Implications</i>	<i>Patient Perspective</i>
Improved Bioavailability	Higher absorption rates compared to oral forms	Studies showing higher plasma concentrations	Enhanced therapeutic efficacy	Less need for frequent dosing
Steady Drug Levels	Maintains consistent plasma levels	Reduced peak-trough fluctuations	More predictable effects	Increased satisfaction
Reduced Side Effects	Lower systemic exposure reduces adverse reactions	Fewer reports of headaches and flushing	Improved tolerability	Better adherence
Rapid Onset of Action	Faster therapeutic effects than oral forms	Quicker relief reported in clinical trials	Suitable for on-demand use	Immediate results
Ease of Use	Non-invasive and convenient application	High patient compliance in studies	Encourages adherence	User-friendly

Reduced First-Pass Metabolism	Bypasses liver metabolism	Evidence of higher effective dose availability	Improved effectiveness for patients	Fewer interactions with other drugs
Potential for Customization	Tailored formulations for individual needs	Ongoing research into personalized patches	Better outcomes for diverse patient needs	Personalized treatment options
Long-lasting Effects	Sustained delivery over extended periods	Studies indicate prolonged therapeutic action	Reduced frequency of administration	Less disruption in daily routine
Adaptability to Patients	Various formulations to suit patient preferences	Research into different application methods	Flexibility in treatment plans	More options for management
Reduced Drug Waste	Efficient delivery minimizes waste	Studies show lower drug quantities required	Cost-effective treatment	More economical

6. Conclusion

Finally, the management of erectile dysfunction and benign prostatic hyperplasia has been revolutionized thanks to the Tadalafil transdermal delivery systems. The problems such as low bioavailability, first pass metabolism, and several side effects reduce patient compliance that hinders traditional oral formulations. However, lately significant advancement has been noted in treating these problems especially with formulations like patches and nano formulations.

Pharmacokinetic advantages of the transdermal Tadalafil consist of; the improved therapeutic effect because of the enhanced bioavailability as well as the avoidance of fluctuations of the drug concentration. Secondly, while the transdermal delivery is slow, it has been credited with reducing the incidence of side effects as patients' tolerance and pleasure increase.

It is a rebound that several new clinical trials suggested that the application of transdermal Tadalafil is almost as effective as oral method is, if not more effective. The potential for additional Tadalafil therapy optimization is being further stressed by further exploring the new approaches to therapy delivering. The potential of a lesser invasive route to deliver Tadalafil is becoming apparent as the field of transdermal drug delivery system emerges. It would be useful to consider that both therapeutic effectiveness and overall quality of life for all patients in general will improve as a result of this change. Future work would remain focused on creating more definitive transdermal formulations and evaluating their usability in different patients. New findings on Transdermal Tadalafil would allow better and more nuanced treatment of erectile dysfunction.

REFERENCES:

1. Fusco F, D'Anzeo G, Sessa A, Pace G, Rossi A, Capece M, d'Emmanuele di Villa Bianca R. BPH/LUTS and ED: Common pharmacological pathways for a common Oct;10(10):2382-93. Simonsen U, García-Sacristán A, Prieto D. Penile arteries and erection. *Journal of vascular research*. 2002 Aug 12;39(4):283-303.
2. Swain S, Beg S, Singh A, Patro N, E Bhanoji Rao M. Advanced techniques for penetration enhancement in transdermal drug delivery system. *Current drug delivery*. 2011 Jul 1;8(4):456-73.
3. Rehman FU, Shah KU, Shah SU, Khan IU, Khan GM, Khan A. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS). *Expert opinion on drug delivery*. 2017 Nov 2;14(11):1325-40.
4. Dubey R, Pothuvan U. Transdermal patches: an emerging mode of drug delivery system in pulmonary arterial hypertension. *Journal of Drug Delivery and Therapeutics*. 2021 Aug 15;11(4-S):176-86.
5. Mitidieri E, Cirino G, di Villa Bianca RD, Sorrentino R. Pharmacology and perspectives in erectile dysfunction in man. *Pharmacology & therapeutics*. 2020 Apr 1;208:107493.
6. Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, Luo Y, Huang J. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. *International urology and nephrology*. 2017 Oct;49:1731-40.
7. Arif SA, Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. *Clinical therapeutics*. 2011 Aug 1;33(8):993-1004.
8. Eadie MJ. Therapeutic drug monitoring—antiepileptic drugs. *British journal of clinical pharmacology*. 1998 Sep;46(3):185-93.
9. Hamzehnejadi M, Ranjbar Tavakoli M, Abiri A, Ghasempour A, Langarizadeh MA, Forootanfar H. A review on phosphodiesterase-5 inhibitors as a topical therapy for erectile dysfunction. *Sexual Medicine Reviews*. 2022 Jul;10(3):376-91.
10. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *Journal of psychosomatic research*. 1999 Dec 1;47(6):555-67.
11. Cramer JA. Enhancing patient compliance in the elderly: role of packaging aids and monitoring. *Drugs & aging*. 1998 Jan;12:7-15.
12. Mehanna MM, Motawaa AM, Samaha MW. Nanovesicular carrier-mediated transdermal delivery of tadalafil: I-formulation and physicochemical characterization. *Drug development and industrial pharmacy*. 2015 May 4;41(5):714-21.
13. Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. *BJU international*. 2001 Oct 1;88(s 3):11-7.
14. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. *Drug delivery*. 2016 Feb 12;23(2):564-78.
15. Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. *Expert opinion on drug delivery*. 2012 Jul 1;9(7):783-804.

16. Ammar HO, Tadros MI, Salama NM, Ghoneim AM. Therapeutic strategies for erectile dysfunction with emphasis on recent approaches in nanomedicine. *IEEE Transactions on NanoBioscience*. 2019 Sep 30;19(1):11-24.
17. Zoabi A, Touitou E, Margulis K. Recent advances in nanomaterials for dermal and transdermal applications. *Colloids and Interfaces*. 2021 Mar 18;5(1):18.
18. Elbardisy B, Galal S, Abdelmonsif DA, Boraie N. Intranasal Tadalafil nanoemulsions: formulation, characterization and pharmacodynamic evaluation. *Pharmaceutical Development and Technology*. 2019 Oct 21;24(9):1083-94.
19. Baek JS, Cho CW. Transdermal delivery of tadalafil using a novel formulation. *Drug Delivery*. 2016 Jun 12;23(5):1571-7.
20. Kim JS, Kim MS, Baek IH. Enhanced bioavailability of tadalafil after intranasal administration in beagle dogs. *Pharmaceutics*. 2018 Oct 15;10(4):187.
21. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. *British journal of clinical pharmacology*. 2006 Mar;61(3):280-8.
22. Gale S. The evolving treatment landscape of pulmonary arterial hypertension. *American Journal of Managed Care*. 2021 Mar 3;27.
23. Gul M, Serefoglu EC. An update on the drug safety of treating erectile dysfunction. *Expert opinion on drug safety*. 2019 Oct 3;18(10):965-75.
24. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database. *International journal of clinical practice*. 2010 Jan;64(2):240-55.
25. Jana S, Kumari Acharjya S, Nahak A, Kumar Dash S, Chakraborty A, Chowdhury B. Application of Modern Analytical Techniques for Quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus. *Current Pharmaceutical Analysis*. 2023 Feb 1;19(2):91-116.
26. Nangare S, Tade RS, Dugam S, Shitole MM. Progress in erectile dysfunction therapy via drug delivery system. *Thai Journal of Pharmaceutical Sciences (TJPS)*. 2020 Jun 15;44(2).
27. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of integrated analyses. *The Journal of urology*. 2002 Oct;168(4 Part 1):1332-6
28. TRANSGENDER HT. MEDICINE, CHICAGO, USA, AUGUST 26–30 2012. *J Sex Med*. 2012;9(4):183-298.
29. Khera M, Howell S. Medical and Surgical Management of Erectile Dysfunction. *Men's Reproductive and Sexual Health Throughout the Lifespan: An Integrated Approach to Fertility, Sexual Function, and Vitality*. 2023 Nov 16:308.
30. Ouranidis A, Tsiixerli A, Vardaka E, Markopoulou CK, Zacharis CK, Nicolaou I, Hatzichristou D, Haidich AB, Kostomitsopoulos N, Kachrimanis K. Sildenafil 4.0—Integrated synthetic chemistry, formulation and analytical strategies effecting immense therapeutic and societal impact in the fourth industrial era. *Pharmaceutics*. 2021 Apr 15;14(4):365.
31. Mao KL, Fan ZL, Yuan JD, Chen PP, Yang JJ, Xu J, ZhuGe DL, Jin BH, Zhu QY, Shen BX, Sohawon Y. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of

curcumin to improve its therapeutic effect on psoriasis mouse model. *Colloids and Surfaces B: Biointerfaces*. 2017 Dec 1;160:704-14.

32. Mohamed SA, Rofaeil RR, Salem H, Elrehany M, Asiri YI, Al Fatease A, Abdelkader H. Proniosomal Gel-Loaded Phosphodiesterase Inhibitors (Sildenafil, Vardenafil, and Tadalafil): Prospects for Topical Penile Therapy of Tadalafil for Treatment of Erectile Dysfunction. *Gels*. 2023 Jul 25;9(8):597.

33. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. *International journal of impotence research*. 2007 Mar;19(2):200-7.

34. Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. *Advanced drug delivery reviews*. 2008 Mar 17;60(6):625-37.

